Recent News
-
Symposium’23 Program
Program here.
“Innovative drugs & health products,
imaging & theranostics agents –
cell & gene biotherapies”, March 17, 2023, 13:30 -
3e matinée Carnot Star “9-12 Recherche-Industrie” dédiée à l’Imagerie, 17 Mars 2023, 8h30
Programme ici, inscriptions ici, . -
FairEmbo en Afrique : “Ce médecin marseillais sauve des femmes avec des bouts de ficelle”
FairEmbo en Afrique : l’Embolisation-pour-tous franchit une nouvelle étape. Plus d’informations ici. -
Webinar: Discover Radiotheranostics in Nuclear Medicine (15 Sept. 2022)
Plus d’informations ici. -
Le projet EmboBio, développé au CERIMED, a reçu le prix de l’innovation AP-HM 2022
Plus d’informations sur le prix AP-HM de l’innovation 2022 ici. Plus d’informations sur le projet Embobio dans cette vidéo. -
CERIMED OBTAINS DUAL ISO 9001:2015 AND NF X50-900:2016 CERTIFICATION FOR ITS PRE-CLINICAL RADIOLOGICAL AND NUCLEAR SERVICE AND INNOVATION ACTIVITIES
On June 5, 2022, the European Center for Research in Medical Imaging (CERIMED, UMS AMU CNRS 2012) obtained dual ISO 9001:2015 and NF-X50-900 certification for its pre-clinical -
Symposium’21 Program
Program here.
“Innovative drugs & health products,
imaging & theranostics agents –
cell & gene biotherapies” -
VECT-HORUS and CERIMED Announce Collaboration to Support the Development of VECT-HORUS’ Theragnostic Agents
VECT-HORUS, a biotechnology company that designs and develops vectors that facilitate the targeted delivery of therapeutic molecules and imaging agents, has announced the signing of a collaboration -
FAIR-Embo hopes to spread safe, cheap embolization around the world
We are proud to anounce that Pr Vincent Vidal (Marseille, France), Head of the Experimental Interventional Radiology Laboratory hosted at CERIMED, and colleagues have demonstrated the in vivo feasibility
Last Publications (10/333)
- Tolboom, N, Verger, A, Albert, NL, Brendel, M, Cecchin, D, Fernandez, PA et al.. EANM position paper: theranostics in brain tumours-the present and the future. Eur J Nucl Med Mol Imaging. 2023; :. doi: 10.1007/s00259-023-06425-8. PubMed PMID:37698647 .
- Albert, NL, Garrigue, P, Guillet, B, Burger, IA. Correction to: Highlights of the 35th EANM Annual Congress 2022, onsite edition in Barcelona, Spain: “FROM BARCELONA WITH LOVE”. Eur J Nucl Med Mol Imaging. 2023; :. doi: 10.1007/s00259-023-06419-6. PubMed PMID:37646835 .
- Cuny, T, Romanet, P, Goldsworthy, M, Guérin, C, Wilkin, M, Roche, P et al.. Cinacalcet reverses short QT interval in Familial Hypocalciuric Hypercalcemia type 1. J Clin Endocrinol Metab. 2023; :. doi: 10.1210/clinem/dgad494. PubMed PMID:37602721 .
- de la Fouchardière, C, Haissaguerre, M, Decaussin-Petrucci, M, Renaudin, K, Deschamps, F, Mirallié, E et al.. [French recommendations for malignant pheochromocytomas and paragangliomas by the national ENDOCAN-COMETE network]. Bull Cancer. 2023; :. doi: 10.1016/j.bulcan.2023.06.002. PubMed PMID:37573200 .
- Abellan Lopez, M, Hutter, L, Pagin, E, Vélier, M, Véran, J, Giraudo, L et al.. In vivo efficacy proof of concept of a large-size bioprinted dermo-epidermal substitute for permanent wound coverage. Front Bioeng Biotechnol. 2023;11 :1217655. doi: 10.3389/fbioe.2023.1217655. PubMed PMID:37560537 PubMed Central PMC10407941.
- Jourde-Chiche, N, Bobot, M, Burtey, S, Chiche, L, Daugas, E. Weaning Maintenance Therapy in Lupus Nephritis: For Whom, When, and How?. Kidney Int Rep. 2023;8 (8):1481-1488. doi: 10.1016/j.ekir.2023.05.012. PubMed PMID:37547513 PubMed Central PMC10403675.
- Horowitz, T, Salgues, B, Padovani, L, Farah, K, Dufour, H, Chinot, O et al.. Optic Nerve Sheath Meningiomas: Solving Diagnostic Challenges with 68Ga-DOTATOC PET/CT. Diagnostics (Basel). 2023;13 (13):. doi: 10.3390/diagnostics13132307. PubMed PMID:37443701 PubMed Central PMC10341062.
- Albert, NL, Garrigue, P, Guillet, B, Burger, IA. Highlights of the 35th EANM Annual Congress 2022, onsite edition in Barcelona, Spain: “FROM BARCELONA WITH LOVE”. Eur J Nucl Med Mol Imaging. 2023; :. doi: 10.1007/s00259-023-06306-0. PubMed PMID:37432447 .
- Sapoval, M, Thiounn, N, Descazeaud, A, Déan, C, Ruffion, A, Pagnoux, G et al.. Prostatic artery embolisation versus medical treatment in patients with benign prostatic hyperplasia (PARTEM): a randomised, multicentre, open-label, phase 3, superiority trial. Lancet Reg Health Eur. 2023;31 :100672. doi: 10.1016/j.lanepe.2023.100672. PubMed PMID:37415648 PubMed Central PMC10320610.
- Benloucif, A, Meyer, D, Balasse, L, Goubard, A, Danner, L, Bouhlel, A et al.. Rapid nanobody-based imaging of mesothelin expressing malignancies compatible with blocking therapeutic antibodies. Front Immunol. 2023;14 :1200652. doi: 10.3389/fimmu.2023.1200652. PubMed PMID:37388728 PubMed Central PMC10303918.
Dernières Publications (10/333)
- Tolboom, N, Verger, A, Albert, NL, Brendel, M, Cecchin, D, Fernandez, PA et al.. EANM position paper: theranostics in brain tumours-the present and the future. Eur J Nucl Med Mol Imaging. 2023; :. doi: 10.1007/s00259-023-06425-8. PubMed PMID:37698647 .
- Albert, NL, Garrigue, P, Guillet, B, Burger, IA. Correction to: Highlights of the 35th EANM Annual Congress 2022, onsite edition in Barcelona, Spain: “FROM BARCELONA WITH LOVE”. Eur J Nucl Med Mol Imaging. 2023; :. doi: 10.1007/s00259-023-06419-6. PubMed PMID:37646835 .
- Cuny, T, Romanet, P, Goldsworthy, M, Guérin, C, Wilkin, M, Roche, P et al.. Cinacalcet reverses short QT interval in Familial Hypocalciuric Hypercalcemia type 1. J Clin Endocrinol Metab. 2023; :. doi: 10.1210/clinem/dgad494. PubMed PMID:37602721 .
- de la Fouchardière, C, Haissaguerre, M, Decaussin-Petrucci, M, Renaudin, K, Deschamps, F, Mirallié, E et al.. [French recommendations for malignant pheochromocytomas and paragangliomas by the national ENDOCAN-COMETE network]. Bull Cancer. 2023; :. doi: 10.1016/j.bulcan.2023.06.002. PubMed PMID:37573200 .
- Abellan Lopez, M, Hutter, L, Pagin, E, Vélier, M, Véran, J, Giraudo, L et al.. In vivo efficacy proof of concept of a large-size bioprinted dermo-epidermal substitute for permanent wound coverage. Front Bioeng Biotechnol. 2023;11 :1217655. doi: 10.3389/fbioe.2023.1217655. PubMed PMID:37560537 PubMed Central PMC10407941.
- Jourde-Chiche, N, Bobot, M, Burtey, S, Chiche, L, Daugas, E. Weaning Maintenance Therapy in Lupus Nephritis: For Whom, When, and How?. Kidney Int Rep. 2023;8 (8):1481-1488. doi: 10.1016/j.ekir.2023.05.012. PubMed PMID:37547513 PubMed Central PMC10403675.
- Horowitz, T, Salgues, B, Padovani, L, Farah, K, Dufour, H, Chinot, O et al.. Optic Nerve Sheath Meningiomas: Solving Diagnostic Challenges with 68Ga-DOTATOC PET/CT. Diagnostics (Basel). 2023;13 (13):. doi: 10.3390/diagnostics13132307. PubMed PMID:37443701 PubMed Central PMC10341062.
- Albert, NL, Garrigue, P, Guillet, B, Burger, IA. Highlights of the 35th EANM Annual Congress 2022, onsite edition in Barcelona, Spain: “FROM BARCELONA WITH LOVE”. Eur J Nucl Med Mol Imaging. 2023; :. doi: 10.1007/s00259-023-06306-0. PubMed PMID:37432447 .
- Sapoval, M, Thiounn, N, Descazeaud, A, Déan, C, Ruffion, A, Pagnoux, G et al.. Prostatic artery embolisation versus medical treatment in patients with benign prostatic hyperplasia (PARTEM): a randomised, multicentre, open-label, phase 3, superiority trial. Lancet Reg Health Eur. 2023;31 :100672. doi: 10.1016/j.lanepe.2023.100672. PubMed PMID:37415648 PubMed Central PMC10320610.
- Benloucif, A, Meyer, D, Balasse, L, Goubard, A, Danner, L, Bouhlel, A et al.. Rapid nanobody-based imaging of mesothelin expressing malignancies compatible with blocking therapeutic antibodies. Front Immunol. 2023;14 :1200652. doi: 10.3389/fimmu.2023.1200652. PubMed PMID:37388728 PubMed Central PMC10303918.